Exicure is a clinical stage biotechnology company developing a new class of immunomodulatory and gene silencing drugs against validated targets. Its 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Its lead programs address diseases from inflammatory disorders to oncology.
State of Ownership
Research Fellow, University of Western Australia
Business Development Associate Director, University of Michigan
Business Development Executive, Nature Publishing Group, Springer Nature
Sales Account Executive, Springer Nature
Director of Sales , SOLABS
Managing Director, Thoroughly Good Consulting